Inactive Instrument

Cassiopea S.p.A.

Equities

SKIN

IT0005108359

Pharmaceuticals

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Cassiopea S.p.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Hyphens Pharma Pte. Ltd., Enters into Exclusive License and Supply Agreements with Cassiopea S.p.A. for Exclusive Rights to Develop and Commercialize Winlevi in 10 Countries Across Southeast Asia CI
Cassiopea Gets SIX Swiss Exchange Nod to Delist After Cosmo Pharmaceuticals Buyback MT
Cassiopea To Delist From Swiss Bourse In March After Takeover By Cosmo Pharmaceuticals MT
Cassiopea to Delist Shares from Swiss Bourse After Takeover by Cosmo MT
Cosmo Closes Public Exchange Offer For Cassiopea After Amassing 97% Stake MT
Cosmo Pharmaceuticals Secures Over 93% Stake in Cassiopea at Tender Closing MT
Cassiopea S.p.A.(SWX:SKIN) dropped from Swiss Performance Index (Price Return) CI
Cosmo Pharmaceuticals N.V. completed the acquisition of an additional 49.9% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 160 million. CI
Cosmo Pharmaceuticals to Start Additional Acceptance Period in Cassiopea Offer MT
Cosmo Pharmaceuticals Wins Shareholders Nod For Cassiopea Stake Deal MT
Cosmo Pharmaceuticals Raises Cassiopea Stake To Over 87% MT
Cassiopea's Partner Launches Winlevi Acne Treatment In US MT
Cosmo Pharmaceuticals N : Initiates Public Exchange Offer For Cassiopea MT
Cosmo Pharmaceuticals Intends to Acquire Cassiopea CI
Cosmo Pharmaceuticals N.V. made an offer to acquire remaining 53.4% stake in Cassiopea S.p.A. from a group of shareholders in a mergers of equal transaction for approximately CHF 210 million. CI
Cassiopea S p A : Female Androgenetic Alopecia Treatment Shows Improvement in Mid-Stage Trial MT
Cassiopea SpA Announces Topline Results of Phase II Proof of Concept Trial of Clascoterone Solution for the Treatment of Androgenetic Alopecia in Females CI
Cassiopea S p A : Concludes License, Supply Deal for Acne Drug Winlevi MT
Cassiopea S p A : H1 Loss Swells to $7 Million MT
Cassiopea S.p.A. Provides Earnings Guidance for the Year 2021 CI
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada CI
Cassiopea S p A : Enters License, Supply Deals for Acne Treatment in North America MT
Sun Pharmaceutical Industries Ltd. and Cassiopea SpA Announces the Signing of License and Supply Agreements for Winlevi® (Clascoterone Cream 1%) in the United States and Canada CI
Cassiopea S.P.A. Announces Board Changes CI
Chart Cassiopea S.p.A.
More charts
Cassiopea SpA is an Italy-based company engaged in the biotechnology and medical research industry. The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing innovative and differentiated medical dermatology products. The Company's current focus is on the topical treatment of acne, androgenic alopecia (''AGA'') and genital warts. Its portfolio comprises four clinical candidates, such as Winlevi, Breezula, CB-06-01 and CB-06-02, for which the Company owns the worldwide rights. These product candidates are based on three chemical entities (''NCE''). They target unmet medical needs and addressable opportunities in the medical dermatology market. The main shareholder of the Company is Cosmo Pharmaceuticals SA.
More about the company
  1. Stock
  2. Equities
  3. Stock Cassiopea S.p.A. - Swiss Exchange
  4. News Cassiopea S.p.A.
  5. Cassiopea S p A : FY20 Loss Grows to $14.5 Million